Transcranial direct current electrical stimulation in combination with aerobic exercise: A pilot study in post-COVID-19 systemic autoimmune rheumatic patients

Table 1 General characteristics of the systemic autoimmune rheumatic disease patients

Patient	Sex	Age (yr)	BMI (kg/m²)	Disease	Disease duration (yr)	Prednisone (mg/d)	IS	Other medications	Comorbidities	Physical activity levels	Initial disease status
#1	F	56	31.7	ASSD	6	0	MTX, LFN	Amitriptyline	SAH	Moderate	MMT-8 = 80; MYOACT = 0
#2	F	39	37.4	RA	15	5	TOF, MTX	Gabapentin, dipyrone	DLP, FM	Low	DAS28 = 5.4; CDAI = 28
#3	F	43	34.3	RA	21	5	TOF, MTX	Dipyrone	SAH, DLP	Low	DAS28 = 5.7; CDAI = 45
#4	F	55	30.4	RA	4	15	TOF	Dipyrone	-	Moderate	DAS28 = 3.2; CDAI = 3
#5	F	29	29.0	SLE	12	5	MMF	Dipyrone	-	Low	SLEDAI = 4
#6	M	56	23.7	SpA	22	0	-	Meloxicam	-	Low	BASDAI = 3.5; ASDAS = 2.5
#7	F	46	35.6	SpA	26	5	MTX, CZP	Tramadol	SAH	Low	BASDAI = 5.6; ASDAS = 3.0
#8	F	53	26.8	SSj	6	0	HCQ	Dipyrone	SAH	Low	ESSDAI = 2
#9	F	57	26.2	SSj	13	0	HCQ	Sertraline	SAH, FM	Low	ESSDAI = 2

ASSD: Antisynthetase syndrome; AZA: Azathioprine; BMI: Body mass index; CPZ: Certolizumab pegol; DLP; Dyslipidemia; F: Female; FM: Fibromyalgia; HCQ: Hydroxychloroquine; IS: Immunosuppressives; LFN: Leflunomide; M: Male; MMF: Mycophenolate mofetil; MTX: Methotrexate; RA: Rheumatoid arthritis; SAH: Systemic arterial hypertension; SLE: Systemic erythematous lupus; SpA: Spondyloarthritis; SSj: Sjögren’s syndrome; tDCS: Transcranial direct current electrical stimulation; TOF: Tofacitinib.